X

Trial Profile

Systemic Chemotherapy Based on Oxaliplatin and 5-fluorouracil, Apatinib Plus Sintilimab for Metastasis ICC: a Single Arm Prospective Study

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 05 Feb 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Oxaliplatin (Primary) ; Rivoceranib (Primary) ; Sintilimab (Primary)
Indications Cholangiocarcinoma
Focus Therapeutic Use

Most Recent Events

01 Feb 2021 Planned End Date changed from 1 Dec 2021 to 1 Feb 2021.
01 Feb 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Feb 2021.
01 Feb 2021 Status has been changed to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com